title: The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
abstract: OBJECTIVE
  Zolmitriptan (Zomig, formerly known as 311C90), a selective 5HT1B/1D agonist is under development as an acute oral treatment for migraine. Despite the use of prophylactic medication, such as propranolol, breakthrough attacks often occur in patients. Consequently we investigated the effects of propranolol on the pharmacokinetics of, and cardiovascular responses to, zolmitriptan.
  
  
  METHODS
  A double-blind, randomized, crossover study of the effects of pre-treatment with propranolol 160 mg daily for 7 days or placebo on the pharmacokinetics and effects on blood pressure of a single 10 mg dose of zolmitriptan in 12 healthy volunteers.
  
  
  RESULTS
  Propranolol increased mean zolmitriptan Cmax and AUC by 56% and 37% respectively; mean t1/2 was prolonged from 3.1 to 4.0 h. Mean Cmax and AUC of the pharmacologically active N-desmethyl metabolite were reduced by 24% and 11% respectively and the metabolite:parent AUC ratio (AUCm/AUCp) fell from 0.46 to 0.26. Mean Cmax and AUC for the inactive indole acetic acid metabolite were both reduced by 13% and AUCm/AUCp from 1.04 to 0.59. A small pressor effect of short duration was observed following zolmitriptan with mean peak rises of 13 and 11 mmHg in systolic and diastolic pressures respectively; propranolol had no effect on the pressor response.
  
  
  CONCLUSIONS
  The results suggest that propranolol inhibits biotransformation of zolmitriptan but with no change in the small pressor response to zolmitriptan. It is therefore unlikely that the pharmacokinetic changes will lead to clinically important changes in pharmacological effects and dosage adjustment of zolmitriptan is not required in patients taking propranolol for migraine prophylaxis.
authors.affiliation: Glaxo Wellcome R&D Ltd, Greenford, Middlesex.
authors.forename: R W
authors.initials: RW
authors.lastname: Peck
authors.forename: E J
authors.initials: EJ
authors.lastname: Seaber
authors.forename: R
authors.initials: R
authors.lastname: Dixon
authors.forename: C G
authors.initials: CG
authors.lastname: Gillotin
authors.forename: B C
authors.initials: BC
authors.lastname: Weatherley
authors.forename: G
authors.initials: G
authors.lastname: Layton
authors.forename: J
authors.initials: J
authors.lastname: Posner
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D019540:Area Under Curve; D001711:Biotransformation; D001794:Blood Pressure / Q000187:drug effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004347:Drug Interactions; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D010080:Oxazoles / Q000493:pharmacokinetics* / Q000494:pharmacology*; D023303:Oxazolidinones; D011433:Propranolol / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000493:pharmacokinetics* / Q000494:pharmacology*; D014363:Tryptamines
chemical_list: D000319:Adrenergic beta-Antagonists; D010080:Oxazoles; D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan; D011433:Propranolol